Impact of the CSM advice on thioridazine on general practitioner prescribing behaviour in Leeds: time series analysis.
In December 2000, the Committee for Safety of Medicines (CSM) advised that thioridazine may prolong QT intervals risking arrhythmias. We investigated the impact on general practitioner prescribing of thioridazine using a time series analysis. Numbers of items and costs of antipsychotics and benzodiazepines prescribed in Leeds from May 1999 until April 2002 were collated. Post-advice, thioridazine prescriptions dropped by 810 items per month (95% confidence interval = 420 to 1200, P < 0.001) but others increased slightly in response. Costs mimicked these changes. Fresh criteria are proposed for appraising the quality of evidence needed to inform future urgent facsimile transmissions.
Wright
Nat M J
NM
Centre for Research in Primary Care, Leeds. n.wright@leeds.ac.uk
Roberts
Alison J
AJ
Allgar
Victoria L
VL
Tompkins
Charlotte N E
CN
Greenwood
Darren C
DC
Laurence
Gillian
G
D014150:Antipsychotic Agents / Q000009:adverse effects*; D017277:Drug Approval; D004739:England; D005194:Family Practice / Q000379:methods*; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D012449:Safety; D012559:Schizophrenia / Q000188:drug therapy*; D013881:Thioridazine / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D013881:Thioridazine